TY - JOUR
T1 - Mortality and readmission rates among hospitalized COVID-19 patients with varying stages of chronic kidney disease
T2 - a multicenter retrospective cohort
AU - the CovidPredict Study Group
AU - Appelman, Brent
AU - Oppelaar, Jetta J.
AU - Broeders, Lani
AU - Wiersinga, Willem Joost
AU - Peters-Sengers, Hessel
AU - Vogt, Liffert
AU - Appelman, Brent
AU - Schinkel, Michiel
AU - Buis, David
AU - Sigaloff, Kim C.E.
AU - Elbers, Paul W.G.
AU - Rusch, Daisy
AU - Reidinga, Auke
AU - Moeniralam, Hazra
AU - Wyers, Caroline
AU - van den Bergh, Joop
AU - Simsek, Suat
AU - van Dam, Bastiaan
AU - van den Gritters, Niels C.
AU - Bokhizzou, Nejma
AU - Brinkman, Kees
AU - de Kruif, Martijn
AU - Dormans, Tom
AU - Douma, Renée
AU - de Haan, Lianne R.
AU - Fung, Tsz Yeung
AU - Beudel, Martijn
AU - CovidPredict Study Group
N1 - Funding Information: This work was supported by Amsterdam UMC and Amsterdam UMC Corona Fund. The following people report grants in the previous 36 months: H. Peters-Sengers report grants of the Dutch Kidney Foundation (KOLFF Grant 19OK009) and W.J. Wiersinga reports a grant from Netherlands Organisation for Health Research and Development (TURN-COVID). Publisher Copyright: © 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.
AB - Chronic kidney disease (CKD) has been recognized as a highly prevalent risk factor for both the severity of coronavirus disease 2019 (COVID-19) and COVID-19 associated adverse outcomes. In this multicenter observational cohort study, we aim to determine mortality and readmission rates of patients hospitalized for COVID-19 across varying CKD stages. We performed a multicenter cohort study among COVID-19 patients included in the Dutch COVIDPredict cohort. The cohort consists of hospitalized patients from March 2020 until July 2021 with PCR-confirmed SARS-CoV-2 infection or a highly suspected CT scan-based infection with a CORADS score ≥ 4. A total of 4151 hospitalized COVID-19 patients were included of who 389 had a history of CKD before admission. After adjusting for all confounding covariables, in patients with CKD stage 3a, stage 3b, stage 4 and patients with KTX (kidney transplantation), odds ratios of death and readmission compared to patients without CKD ranged from 1.96 to 8.94. We demonstrate an evident increased 12-week mortality and readmission rate in patients with chronic kidney disease. Besides justified concerns for kidney transplant patients, clinicians should also be aware of more severe COVID-19 outcomes and increased vulnerability in CKD patients.
UR - http://www.scopus.com/inward/record.url?scp=85124445847&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41598-022-06276-7
DO - https://doi.org/10.1038/s41598-022-06276-7
M3 - Article
C2 - 35145189
SN - 2045-2322
VL - 12
SP - 2258
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 2258
ER -